Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis

Journal of Medical Economics · Available online 21 Jun 2026 · In press · DOI 10.1080/13696998.2026.2681352

Free full text

Authors (10)

Jeffrey Kaplan, Dana Beenstock, Martin Belkin, Heidi Crayton, Christopher Eckstein, Ruth Fredericks, Boyang Bian, Nicholas Belviso, Daphne Ni, Danette Rutledge

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kaplan, J., Beenstock, D., Belkin, M., et al. (2026). Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis. Journal of Medical Economics. https://doi.org/10.1080/13696998.2026.2681352

Related articles

• Response to Kirshner et al.: updated cost consequence analyses using requested inputs · Journal of Medical Economics · 2026 · Same journal
• Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia · Journal of Medical Economics · 2026 · Same journal
• Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis · Journal of Medical Economics · 2026 · Same journal
• Interpreting per-death productivity estimates in human capital analyses of lung cancer: the role of working-age-restricted denominators · Journal of Medical Economics · 2026 · Same journal
• An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma · Journal of Medical Economics · 2026 · Same journal
• A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia · Journal of Medical Economics · 2026 · Same journal
• The financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust · Journal of Medical Economics · 2026 · Same journal
• From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis · Journal of Medical Economics · 2026 · Same journal
• Cost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia · Journal of Medical Economics · 2026 · Same journal
• Impact of Crohn’s perianal fistulas on healthcare resource utilization: a US chart review study · Journal of Medical Economics · 2026 · Same journal